Business Context and Reporting Period
Evaxion A/S, a clinical-stage TechBio company specializing in AI-Immunology powered vaccines, filed this Form 6-K on April 7, 2026. The filing reports a significant clinical milestone for its personalized cancer vaccine, EVX-01.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development update rather than financial performance.
Material Changes
The primary material event is the announcement that the last patient visit has been completed in the one-year extension of the Phase 2 trial for EVX-01. This marks a key progression in the clinical evaluation of the company's lead asset.
Guidance, Outlook, and Risks
Management commentary is limited to the press release regarding the trial milestone. The filing does not contain updated financial guidance, specific risk factors, or details on contingencies beyond the standard incorporation by reference of prior registration statements.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the Phase 2 trial extension results.
- Review the most recent Form 20-F or quarterly reports for current cash runway and burn rate, as this filing contains no financial data.
- Confirm the timeline for the final analysis of the EVX-01 Phase 2 trial data.
- Check for any subsequent filings regarding the regulatory strategy following the completion of patient visits.